Cellectar Biosciences, Inc. (CLRB) Files Form 4 Insider Buying : Richard Hertzberg Buys 238,500 Shares

Cellectar Biosciences, Inc. (CLRB): Richard Hertzberg , other of Cellectar Biosciences, Inc. purchased 238,500 shares on Apr 15, 2016. The Insider buying transaction was reported by the company on Jun 14, 2016 to the Securities and Exchange Commission. The shares were purchased at $2.01 per share for a total value of $504,793.22 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 21, 2016, Paul L Berns (director) purchased 117,371 shares at $2.12 per share price.On Apr 21, 2016, James V Caruso (CEO) purchased 46,948 shares at $2.12 per share price.Also, On Apr 21, 2016, Stephen A Hill (director) purchased 9,390 shares at $2.12 per share price.On Apr 21, 2016, John Neis (director) purchased 234,742 shares at $2.12 per share price.

Shares of Cellectar Biosciences Inc (CLRB) ended Friday, Jun 10, 2016 session in red amid volatile trading. The shares closed down -0.15 points or -4.36% at $3.29 with 3,47,596 shares getting traded. Post opening the session at $3.35, the shares hit an intraday low of $3.26 and an intraday high of $3.48 and the price vacillated in this range throughout the day. The company has a market cap of $13 M and the number of outstanding shares has been calculated to be 38,32,405 shares. The 52-week high of Cellectar Biosciences Inc is $38.89 and the 52-week low is $1.

Cellectar Biosciences Inc Money Flow Index Chart

Cellectar Biosciences Inc. formerly Novelos Therapeutics Inc. is a biopharmaceutical company. The Company is engaged in developing compounds for the treatment diagnosis and imaging of cancer. Its product candidates include I-124-CLR1404 I-131-CLR1404 and CLR1502. Its product candidates are based on a cancer-targeting delivery platform of optimized phospholipid ether (PLE) analogs that interact with lipid rafts. I-131-CLR1404 is a small-molecule broad-spectrum cancer-targeting molecular radiotherapeutic that is a radiotherapeutic agent to use PLEs to target cancer cells. CLR1502 is a small-molecule broad-spectrum cancer-targeting non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.

Leave a Reply

Cellectar Biosciences Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Cellectar Biosciences Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.